Please ensure Javascript is enabled for purposes of website accessibility

Valeant Pharmaceuticals Reports Big Q3 Loss on Lower Product Sales

By Keith Speights – Nov 8, 2016 at 6:23AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker's revenue slid due largely to paying higher rebates on its main drugs.

Image source: Getty Images.

Valeant Pharmaceuticals (BHC 0.52%) announced its third-quarter earnings results before the market opened on Tuesday. With Valeant's stock plunging over 20% in early trading, it's obvious that the results weren't good. Here's what you need to know about the beleaguered drugmaker's third-quarter performance. 

Valeant results: The raw numbers


Q3 2016 Actuals

Q3 2015 Actuals

Change (YOY)


$2.48 billion

$2.79 billion


Net income (loss)

($1.22 billion)

$49.5 million


Net income (loss) per diluted share




YOY = year over year. Data source: Valeant Pharmaceuticals.

What happened this quarter?

Valeant attributed its decline in revenue primarily to lower sales for current products. The company said that negative effects of currency exchange along with the impact of divestitures and discontinuations also hurt revenue in the third quarter.

Those lower sales for current products occurred in nearly every area of Valeant's business. Branded prescription sales fell 23% year over year to $847 million in large part due to paying higher rebates. Valeant's U.S. diversified products segment saw sales drop 16% from the prior-year period to $471 million. The primary issue for this segment related to generic competition.

The only area of Valeant's business to post sales growth was the Bausch + Lomb/international segment. However, even that growth was relatively weak. The segment's revenue increased 4% year over year to $1.16 billion. 

Why did Valeant's bottom line get shellacked well beyond the revenue decline? The main reason was that the company recognized a goodwill impairment charge of $1.05 billion. Valeant wrote off this large amount largely because the value of the Salix Pharmaceuticals business acquired in 2015 has deteriorated.

What management had to say

Chairman and CEO Joseph Papa didn't talk much about the third-quarter results, choosing to instead focus on the changes that Valeant is making. Papa said:

This past quarter, we made further progress toward establishing the new Valeant. We have, where appropriate, begun to centralize some parts of the business, and hired two key senior executives: Paul Herendeen, Chief Financial Officer, and Dr. Louis Yu, Chief Quality Officer.  We also have started to present our financial results under three operating and reportable segments, which we believe will help clarify areas of strength and provide additional transparency. While we have revised our expectations for the remainder of 2016, I continue to be encouraged by the commitment of our employees who work each day toward meeting our mission of helping improve people's lives through our healthcare products.

Looking forward

As Papa's comments indicated, Valeant lowered its outlook for the rest of 2016. The company now expects total revenue for the year to be between $9.55 billion and $9.65 billion. That's down from the company's previous guidance range of $9.9 billion to $10.1 billion. Adjusted non-GAAP earnings per share are now expected to be between $5.30 and $5.50, down from the previous range of $6.60 to $7.00. 

Probably the most worrisome thing for Valeant is its big debt load. The company reported long-term debt as of Sept. 30 totaling nearly $30.4 billion. That's over $100 million higher than the debt figure at the end of 2015. 

Rumors flew recently that Valeant might sell Salix. A sale of this business could help Valeant reduce some of that large debt load. However, selling Salix would also deprive Valeant of a key source for potential growth.

If Valeant can stabilize its revenue and earnings and sell off more key assets to reduce debt, the company could turn things around. For now, it's a game of wait and see for investors.

Keith Speights has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Valeant Pharmaceuticals. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.